TrialJournal for immunotherapy of cancer2024

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.

Dirk Schadendorf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.